NO972882L - Kjemiske forbindelser - Google Patents

Kjemiske forbindelser

Info

Publication number
NO972882L
NO972882L NO972882A NO972882A NO972882L NO 972882 L NO972882 L NO 972882L NO 972882 A NO972882 A NO 972882A NO 972882 A NO972882 A NO 972882A NO 972882 L NO972882 L NO 972882L
Authority
NO
Norway
Prior art keywords
enzyme
host
prodrug
component
natural
Prior art date
Application number
NO972882A
Other languages
English (en)
Norwegian (no)
Other versions
NO972882D0 (no
Inventor
Christopher John Taylorson
Hendrikus Johannes Eggelte
Antonio Tarragona-Fiol
Brian Robert Rabin
Francis Thomas Boyle
John Frederick Hennam
David Charles Blakey
Peter Robert Marsham
David William Heaton
David Huw Davies
Anthony Michael Slater
Laurent Francois And Hennequin
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO972882(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO972882D0 publication Critical patent/NO972882D0/no
Publication of NO972882L publication Critical patent/NO972882L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • External Artificial Organs (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO972882A 1994-12-23 1997-06-20 Kjemiske forbindelser NO972882L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
PCT/GB1995/002991 WO1996020011A1 (fr) 1994-12-23 1995-12-21 Composes chimiques

Publications (2)

Publication Number Publication Date
NO972882D0 NO972882D0 (no) 1997-06-20
NO972882L true NO972882L (no) 1997-08-19

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972882A NO972882L (no) 1994-12-23 1997-06-20 Kjemiske forbindelser

Country Status (23)

Country Link
US (1) US5985281A (fr)
EP (1) EP0806964B1 (fr)
JP (1) JP3805365B2 (fr)
KR (1) KR100270650B1 (fr)
CN (1) CN1095677C (fr)
AT (1) ATE222124T1 (fr)
AU (1) AU701916B2 (fr)
BR (1) BR9510490B1 (fr)
CA (1) CA2205091A1 (fr)
CZ (1) CZ195297A3 (fr)
DE (1) DE69527805T2 (fr)
ES (1) ES2181805T3 (fr)
FI (1) FI972683A0 (fr)
HU (1) HUT77450A (fr)
IL (1) IL116511A0 (fr)
MX (1) MX9704575A (fr)
NO (1) NO972882L (fr)
NZ (1) NZ297529A (fr)
PL (1) PL184031B1 (fr)
RU (1) RU2189251C2 (fr)
SK (1) SK80997A3 (fr)
TR (1) TR199501654A2 (fr)
WO (1) WO1996020011A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK19498A3 (en) 1995-08-16 1998-09-09 Zeneca Ltd Conjugates containing carboxypeptidase b mutated form and method and use of said conjugates
SG71046A1 (en) 1996-10-10 2000-03-21 Connector Systems Tech Nv High density connector and method of manufacture
WO1998035988A1 (fr) * 1997-02-14 1998-08-20 Zeneca Limited Proteines
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
AU763628B2 (en) * 1998-09-18 2003-07-31 Immunomedics Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
CA2382725A1 (fr) * 1999-09-17 2001-03-22 Genzyme Transgenics Corporation Proteines de fusion produites de maniere transgenique
CA2506629A1 (fr) * 2002-11-27 2004-06-17 Gtc Biotherapeutics, Inc. Production stable d'anticorps modifies dans le lait, et procedes de production
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
CN103435695A (zh) * 2005-10-21 2013-12-11 Gtc生物治疗有限公司 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途
WO2007149827A2 (fr) * 2006-06-20 2007-12-27 Janssen Pharmaceutica, N.V. Méthode pour moduler les propriétés pharmacocinétiques et le métabolisme d'un agent thérapeutique
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2077991B1 (fr) 2006-10-03 2014-02-26 Techfields Biochem Co. Ltd Promédicaments de moutardes hydrosolubles à charge positive et composés apparentés présentant des taux de pénétration cutanée très élevés
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009134389A2 (fr) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. Anticorps anti-cd137 en tant qu'agent dans le traitement d'états inflammatoires
US10745492B1 (en) * 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
EP0454783B1 (fr) * 1989-01-23 1995-06-07 Akzo Nobel N.V. Activation in vivo specifique a un site de medicaments therapeutiques
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
CA2127126A1 (fr) * 1992-01-30 1993-08-05 Helen M. Wilks Synthese chirale au moyen d'enzymes modifiees
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
CN1171054A (zh) 1998-01-21
US5985281A (en) 1999-11-16
ES2181805T3 (es) 2003-03-01
WO1996020011A1 (fr) 1996-07-04
EP0806964B1 (fr) 2002-08-14
DE69527805D1 (de) 2002-09-19
CA2205091A1 (fr) 1996-07-04
CN1095677C (zh) 2002-12-11
ATE222124T1 (de) 2002-08-15
TR199501654A3 (fr) 1996-07-21
CZ195297A3 (en) 1997-12-17
HUT77450A (hu) 1998-04-28
SK80997A3 (en) 1998-02-04
NZ297529A (en) 1999-07-29
NO972882D0 (no) 1997-06-20
IL116511A0 (en) 1996-07-23
PL184031B1 (pl) 2002-08-30
MX9704575A (es) 1997-10-31
DE69527805T2 (de) 2003-04-24
TR199501654A2 (tr) 1996-07-21
JPH10511547A (ja) 1998-11-10
BR9510490A (pt) 1998-01-13
JP3805365B2 (ja) 2006-08-02
FI972683A (fi) 1997-06-19
AU4269796A (en) 1996-07-19
BR9510490B1 (pt) 2010-10-05
RU2189251C2 (ru) 2002-09-20
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
EP0806964A1 (fr) 1997-11-19
AU701916B2 (en) 1999-02-11
FI972683A0 (fi) 1997-06-19

Similar Documents

Publication Publication Date Title
NO972882D0 (no) Kjemiske forbindelser
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
DE69329735D1 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
DE69942578D1 (de) Bifunktionelle moleküle sowie darauf basierende therapien.
BR0210225A (pt) Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
WO1998008542A3 (fr) Composes et procedes destines au traitement et au diagnostic d'infections mycobacteriennes
EP0689586B8 (fr) Activite et fonction de la proteine virale r
WO1999065517A3 (fr) Compositions therapeutiques produisant une reponse immunitaire par renouvellement des antigenes
AU2002360350A1 (en) Peptides that home to tumor lymphatic vasculature and methods of using same
BR9610050A (pt) Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo
MX9802809A (es) Ureasa para el tratamiento de infecciones de helicobacter pylori.
IT1274592B (it) Composizione farmaceutica per la terapia tumorale contenente xenoantigeni
TW332816B (en) Peptide and carbohydrate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application